GRAIL Announces $390 Million Series D Financing

On May 6, 2020 GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, reported a $390 million Series D financing round (Press release, Grail, MAY 6, 2020, View Source [SID1234557164]). New investors including Public Sector Pension Investment Board (PSP Investments) and Canada Pension Plan Investment Board (CPP Investments), as well as two undisclosed investors, joined existing backers including Illumina, Inc. in this round of funding.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"GRAIL is making significant progress with our blood-based, multi-cancer early detection test," said Hans Bishop, Chief Executive Officer at GRAIL. "Nearly 80 percent of cancer deaths result from cancers for which there is no screening test today, and GRAIL’s mission is to change that through the early detection and localization of more than 50 cancers. Enabling this through a single blood draw could improve patient access and adherence to cancer screening and address disparities in cancer care by improving access for rural, vulnerable, and under-served populations. We are delighted that such a high-quality group of investors share our vision and recognize the public health benefits of our technology."

The Series D funding adds to the company’s balance sheet and will support continued development and commercialization of GRAIL’s multi-cancer early detection blood test. Since early 2016, GRAIL has raised more than $1.9 billion in four rounds of equity financing to pursue reducing cancer mortality worldwide through multi-cancer early detection.

About GRAIL’s Multi-Cancer Early Detection Test

GRAIL’s multi-cancer early detection test is designed to detect cancers in early stages, when the chance of survival is higher than if cancer is detected after symptoms appear. Clinical data have shown the ability of this technology to detect more than 50 cancer types with a very low false positive rate of less than one percent. GRAIL’s test was designed to minimize false positives in order to limit associated harms, including patient anxiety and unnecessary diagnostic workups. When a cancer signal is detected, the test has been able to identify where in the body the cancer is located with high accuracy, an important step to guiding diagnostic next steps and care.

GRAIL’s methylation-based technology preferentially targets the most informative regions of the genome and is designed to use its proprietary database and machine-learning algorithms to both detect the presence of cancer and identify the tumor’s tissue of origin. GRAIL believes its sequencing database of cancer and non-cancer methylation signatures is the largest of its kind.

United Therapeutics Corporation To Present At The BofA Securities Virtual Health Care Conference 2020

On May 6, 2020 United Therapeutics Corporation (Nasdaq: UTHR) reported that Mr. James Edgemond, Chief Financial Officer and Treasurer of United Therapeutics, will provide an overview and update on the company’s business at the BofA Securities Virtual Health Care Conference 2020 (Press release, United Therapeutics, MAY 6, 2020, View Source [SID1234557180]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will take place on Wednesday, May 13, 2020, from 4:20 to 4:50 p.m., Eastern Daylight Time, and can be accessed via a live webcast on the United Therapeutics website at View Source under the "Investors" tab in the "Events and Presentations" section. An archived, recorded version of the presentation will be available approximately twenty-four hours after the session ends and can be accessed at the same location for 90 days.

VBI Vaccines Announces First Quarter 2020 Financial Results and Provides Corporate Update

On May 6, 2020 VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, reported financial results for the first quarter ending March 31, 2020 and provided a corporate update (Press release, VBI Vaccines, MAY 6, 2020, View Source [SID1234557090]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

President and CEO, Jeff Baxter, commented, "The last several months have brought unprecedented public health and societal challenges. Science and technology are at the forefront of everyone’s mind, and since the outbreak of COVID-19 there has been a renewed interest in the vaccine space. An effective COVID-19 vaccine is vital to enabling the return to normalcy. We need the collaboration of many great minds to solve this crisis, and we are aggressively working to be part of the solution with our recently announced pan-coronavirus vaccine candidate. Our candidate, VBI-2901, co-expresses SARS-CoV-2, SARS-CoV, and MERS-CoV spike proteins in a multivalent construct that could allow for the production of broadly reactive antibodies, which may also offer potential protection from mutated strains of COVID-19 that may emerge over time. In collaboration with the National Research Council of Canada (NRC), we are evaluating and selecting the optimal vaccine candidate, with the goal of having clinical study material available in Q4 2020. Additionally, we aim to provide periodic updates on the candidate development throughout 2020.

"In this time of heightened public health focus and awareness, we continue to fire on all cylinders as we work to address other significant public health needs. Following the successful completion of the pivotal Phase 3 program for Sci-B-Vac, our tri-antigenic prophylactic hepatitis B vaccine, we are working with the FDA, EMA, and Health Canada to prepare for submissions of regulatory approval applications in the U.S., Europe, and Canada, beginning in the fourth quarter of 2020. Additionally, the clinical trials for our hepatitis B immunotherapeutic and our glioblastoma (GBM) cancer vaccine immunotherapeutic candidates have not yet been materially impacted by the COVID-19 pandemic and are currently on-track for their respective clinical data readouts expected later in 2020.

"We have been working hard to ensure the safety and health of all employees while also continuing to achieve key program milestones. This balance has required tremendous dedication, flexibility, and communication from every member of the VBI team. With net proceeds of approximately $54 million from our recent equity raise added to the balance sheet, we believe we are now well-positioned to capitalize on the growth and value-driving opportunities ahead."

Recent Highlights and Upcoming Program Milestones

Equity Financing

●April 2020: $57.5 million of gross proceeds raised in an underwritten public offering, resulting in net cash proceeds to the company of approximately $54 million.

Appointment of New Board Member

●March 2020: Damian Braga, former Senior Vice President, Global Commercial Operations and President, U.S. and the Americas, of Sanofi Pasteur, joined VBI’s Board of Directors.

Sci-B-Vac: Tri-antigenic Prophylactic Hepatitis B (HBV) Vaccine

●January 2020: Positive top-line results from second pivotal Phase 3 study, CONSTANT, demonstrated lot-to-lot manufacturing consistency, high seroprotection rates and antibody titers, safety and tolerability.
●Q2 2020: Pre-BLA discussions expected with the FDA.
●Q4 2020: Submission of applications for regulatory approvals in the U.S., Europe, and Canada expected to begin.

VBI-2601 (BRII-179): HBV Immunotherapeutic Candidate

●H2 2020: Initial human proof-of-concept data expected from Phase 1b/2a study.

VBI-1901: Cancer Vaccine Immunotherapeutic Candidate

●February 2020: Dosing of the 10 patients in the VBI-1901 + GSK’s AS01B adjuvant system study arm began.
●March 2020: Overall survival (OS) data from Part A VBI-1901 + GM-CSF study arm demonstrated 12-month OS rates of 83% (n=5/6) among vaccine responders vs. 33% (n=3/9) for vaccine non-responders, and a 6.25-month improvement in median OS among vaccine responders (14.0 months) vs. non-responders (7.75 months).
●April 2020: Based upon review of safety data from the first three patients enrolled, the independent Data and Safety Monitoring Board (DSMB) unanimously recommended continuation of the Phase 2a VBI-1901 + AS01B study arm without modification.
●Mid-year 2020: Expanded immunologic, tumor, and clinical data expected from the Phase 2a VBI-1901 + GM-CSF study arm.
●Q4 2020: Initial immunologic and tumor response data expected from the Phase 2a VBI-1901 + AS01B study arm.

VBI-2901: Trivalent Prophylactic Pan-Coronavirus Candidate

●March 2020: As part of a collaboration with the NRC, preclinical development began on a pan-coronavirus vaccine targeting COVID-19, severe acute respiratory syndrome (SARS), and Middle East respiratory syndrome (MERS).
●Q2 2020: IND-enabling pre-clinical animal models expected to begin.
●Q4 2020: Clinical study materials expected to be available for clinical studies.

First Quarter 2020 Financial Results

●Cash Position: VBI ended the first quarter of 2020 with $35.8 million in cash and cash equivalents compared to $44.2 million as of December 31, 2019. Cash position at March 31, 2020, does not include approximately $54 million of net cash proceeds from the April 2020 underwritten public offering.
●Net Cash Used in Operating Activities: Net cash used in operations for the three months ended March 31, 2020 was $7.6 million compared to $14.0 million for the same period in 2019. This decrease was due to completion of the Sci-B-Vac Phase 3 clinical studies.
●Cash Used for Purchase of Property and Equipment: Cash used for the purchase of property and equipment was $0.1 million for the three months ended March 31, 2020 compared to $1.9 million for the same period in 2019. The difference is due to capital purchases and replacements related to the modernization and capacity increases of our manufacturing facility in Rehovot, Israel, that occurred in the first quarter of 2019. The modernization and capacity increases were completed in May 2019.
●Revenue: Revenue in the first quarter of 2020 was $0.42 million, compared to $0.36 million for the same period in 2019. This increase was due to an increase in named-patient sales of Sci-B-Vac in Europe.
●Cost of Revenues: Cost of Revenues was $2.6 million for the first quarter of 2020 compared to $1.2 million in the same period of 2019. The increase is due to re-commencement of manufacturing at the facility in Rehovot and the related costs.
●Research and Development (R&D): R&D expenses were $3.2 million for the first quarter of 2020, compared to $9.0 million for the same period in 2019. The decrease in R&D expenses is the result of the decrease in costs related to the Sci-B-Vac Phase 3 clinical studies, the first of which (PROTECT) completed in June 2019, the second of which (CONSTANT) completed in January 2020.
●General and Administrative (G&A): G&A expenses were $4.1 million for the first quarter of 2020, compared to $4.0 million for the same period in 2019. This slight increase is due to the increase in pre-commercial activities for Sci-B-Vac, but is largely offset by the allocation of certain cost of revenues, related to the temporary closure of the Rehovot facility, in the first quarter of 2019 that did not reoccur during the first quarter of 2020.
●Net Loss: Net loss and net loss per share for the first quarter of 2020 were $8.4 million and $0.05, respectively, compared to a net loss of $14.6 million and a net loss per share of $0.15 for the first quarter of 2019.

Exact Sciences Announces First Quarter 2020 Results

On May 6, 2020 Exact Sciences Corp. (Nasdaq: EXAS) reported that the company generated revenue of $347.8 million for the first quarter ended Mar. 31, 2020, compared to $162.0 million for the same period of 2019 (Press release, Exact Sciences, MAY 6, 2020, View Source [SID1234557131]).

"Even in unprecedented times, cancer doesn’t stop. The coronavirus pandemic highlights and increases the need for novel ways to screen for cancer, detect it early, and guide treatment. Our Cologuard, Oncotype DX, and Paradigm tests meet that need," said Kevin Conroy, chairman and CEO. "In a world that is trying to avoid unnecessary physician office visits, invasive procedures, and treatments, our tests and deep pipeline are more valuable now than ever. We plan to play an even greater role in cancer screening and guiding therapy decisions after the coronavirus pandemic abates."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

First Quarter 2020 Financial Results

For the three-month period ended March 31, 2020, as compared to the same period of 2019 (where applicable):

Total revenue was $347.8 million, compared to $162.0 million

Screening revenue was $219.5 million, an increase of 35 percent

Precision Oncology revenue was $128.4 million

Gross margin including amortization of acquired intangible assets was 71 percent, and non-GAAP gross margin excluding amortization of acquired intangible assets was 77 percent

Net loss was $105.7 million, or $0.71 per share, compared to a net loss of $82.9 million, or $0.66 per share

EBITDA was $(51.0) million and adjusted EBITDA was $(8.2) million

Non-cash interest expense related to convertible debt was $22.5 million, which included a non-cash loss on extinguishment of debt of $8.0 million, compared to $19.6 million, which included a non-cash loss on extinguishment of debt of $10.6 million

Cash, cash equivalents, and marketable securities were $1.2 billion at the end of the quarter, including $975.5 million, net, raised in relation to the issuance of new convertible notes and the repayment of a portion of previously issued convertible notes

Screening includes laboratory service revenue from Cologuard and revenue from Biomatrica products. Precision Oncology includes laboratory service revenue from global Oncotype DX products and the recent Paradigm acquisition.

Non-GAAP Disclosure
In addition to the company’s financial results determined in accordance with U.S. GAAP, the company provides non-GAAP measures that it determines to be useful in evaluating its operating performance. The company presents EBITDA, adjusted EBITDA, as well as non-GAAP gross margin and non-GAAP gross profit. EBITDA and adjusted EBITDA consist of net loss after adjustment for those items shown in the table below. The company defines non-GAAP gross profit and non-GAAP gross margin as GAAP gross profit and GAAP gross margin, respectively, excluding amortization of acquired intangible assets. The amortization of acquisition-related intangible assets used in the calculation of non-GAAP gross profit and non-GAAP gross margin pertain only to the amortization associated with developed technology acquired and recorded through purchase accounting transactions. The amortization of these intangible assets will recur in future periods until such intangible assets have

been fully amortized. The company believes that these non-GAAP measures are useful in evaluating the company’s operating performance. The company uses this non-GAAP financial information to evaluate ongoing operations and for internal planning and forecasting purposes. Non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental information purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with U.S. GAAP. For example, non-GAAP gross margin and non-GAAP gross profit exclude the amortization of acquired intangible assets although such measures include the revenue associated with the acquisitions. For a reconciliation of these non-GAAP measures to GAAP, see below "EBITDA and Adjusted EBITDA Reconciliations."

First Quarter Conference Call & Webcast
Company management will host a conference call and webcast on Wednesday, May 6, 2020, at 5 p.m. ET to discuss first quarter 2020 results. The webcast will be available at www.exactsciences.com. Domestic callers should dial 833-235-7650 and international callers should dial +1-647-689-4171.

An archive of the webcast will be available at www.exactsciences.com. A replay of the conference call will be available by calling 800-585-8367 domestically or 416-621-4642 internationally. The access code for the replay of the call is 7874149. The webcast, conference call and replay are open to all interested parties.

About Cologuard
Cologuard was approved by the FDA in August 2014, and results from Exact Sciences’ prospective 90-site, point-in-time, 10,000-patient pivotal trial were published in the New England Journal of Medicine in March 2014. Cologuard is included in the American Cancer Society’s (2018) colorectal cancer screening guidelines and the recommendations of the U.S. Preventive Services Task Force (2016) and National Comprehensive Cancer Network (2016). Cologuard is indicated to screen adults 45 years of age and older who are at average risk for colorectal cancer by detecting certain DNA markers and blood in the stool. Do not use Cologuard if you have had precancer, have inflammatory bowel disease and certain hereditary syndromes, or have a personal or family history of colorectal cancer. Cologuard is not a replacement for colonoscopy in high risk patients. Cologuard performance in adults ages 45-49 is estimated based on a large clinical study of patients 50 and older. Cologuard performance in repeat testing has not been evaluated.

The Cologuard test result should be interpreted with caution. A positive test result does not confirm the presence of cancer. Patients with a positive test result should be referred for diagnostic colonoscopy. A negative test result does not confirm the absence of cancer. Patients with a negative test result should discuss with their doctor when they need to be tested again.

Medicare and most major insurers cover Cologuard. For more information about Cologuard, visit www.cologuardtest.com. Rx only.

About Oncotype DX
The Oncotype DX portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions. In breast cancer, the Oncotype DX Breast Recurrence Score test is the only test that has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer. Additionally, the Oncotype DX Breast DCIS Score test predicts the likelihood of recurrence in a pre-invasive form of breast cancer called DCIS. In prostate cancer, the Oncotype DX Genomic Prostate Score test predicts disease aggressiveness and further clarifies the current and future risk of the cancer prior to treatment intervention, and the Oncotype DX AR-V7 Nucleus Detect test helps determine which patients with metastatic castration-resistant prostate cancer (mCRPC) are resistant to androgen receptor (AR)-targeted therapies. The Oncotype DX AR-V7 Nucleus Detect test is performed by Epic Sciences at its centralized, CLIA-certified laboratory in San Diego and offered exclusively by Exact Sciences. With more than 1 million patients tested in more than 90 countries, the Oncotype DX tests have redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment. To learn more about Oncotype DX tests, visit www.OncotypeIQ.com, www.MyBreastCancerTreatment.org or www.MyProstateCancerTreatment.org.

Saniona publishes its interim report for the first quarter 2020

On May 6, 2020 Saniona reported that its interim report for the first quarter 2020 (Press release, Saniona, MAY 6, 2020, View Source [SID1234557146])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Financial highlights

Q1 2020 (Q1 2019)
· Net revenues were SEK 0.5 M (1.7 M)
· EBIT was SEK -30.6 M (-29.1 M)
· Net profit/loss was SEK -28.2 M (-24.8)
· Earnings per share were SEK -0.96 (-1.06)
· Diluted earnings per share were SEK -0.96 (-1.06)

Business highlights in Q1 2020

In January, Saniona appointed Rami Levin as its President and Chief Executive Officer. Rami Levin will oversee the transformation of Saniona to a fully integrated rare disease biopharmaceutical company. He has extensive commercial experience in CNS and rare diseases, both in U.S. and globally. Jørgen Drejer, previous CEO, was appointed Chief Scientific Officer.
In January, Saniona completed a private placement of SEK 25 million and proposed a financing of up to SEK 158 million comprising a combination of the directed issue and rights issue of warrants totaling SEK 111 million – 133 million at a strike price of SEK 25 – 30 per share as well as a loan facility of SEK 25 million.
On February 18, 2020, Saniona co-founded new migraine therapy company Cephagenix.
CFO Thomas Feldthus has left the company and Saniona has initiated a search for a new, U.S.-based CFO. Anita Milland, the current VP of Finance and Administration, was appointed interim CFO and Head of IR, and Jørgen Drejer assumed the role of Deputy CEO.
On 18 March 2020, Saniona announced the completion of its the six-month double-blind Phase 2 trial of Tesomet in hypothalamic obesity.
In March, Saniona signed a second research collaboration agreement with Boehringer Ingelheim in schizophrenia.

Significant events after the reporting period

In April, Saniona reported positive topline results from its Phase 2 Trial of Tesomet in Hypothalamic Obesity. The double-blind placebo controlled results showed that Tesomet was safe and well tolerated and on its main efficacy end points it showed that Tesomet was statistically significantly different than placebo.
Saniona reported the appointment of Rudolf Baumgartner, M.D., as Chief Medical Officer and Head of Clinical Development. Dr. Baumgartner will be based in the US, along with CEO Rami Levin.